idoxifene

idoxifene

Oncology A selective estrogen receptor modulator–SERM in clinical trials for treating advanced breast CA and preventing osteoporosis. See Breast cancer, Osteoporosis, SERM.
References in periodicals archive ?
Induction of hepatic aneuploidy in vivo by tamoxifen, toremifene and idoxifene in female Sprague-Dawley rats.
Comparison between liquid chromatography-time-of -flight mass spectrometry and selected reaction monitoring liquid chromatography-mass spectrometry for quantitative determination of idoxifene in human plasma.
Arzoxifene therefore joins an expanding list of selective estrogen receptor modulators (SERMs) that did not make it out of clinical trials: idoxifene, droloxifene, levormeloxifene, and lasofoxifene (approved in Europe, however), to name a few.
Large-scale clinical trials of a designer estrogen known as idoxifene were recently canceled after several years because, like estrogen and tamoxifen, the compound seemed to boost a woman's chance of developing endometrial cancer.
So far, there is no evidence that tamoxifen, raloxifene, and idoxifene consistently distinguish between the two receptors, says Donald P.
Chief executive Mr Jan Leschly said the company had stopped development of Idoxifene for osteoporosis, though, it is still being developed for the treatment of breast cancer.
The company's hopes are riding on four new products highlighted in a research and development review in April; Avandia for non-insulin dependent diabetes, Idoxifene for osteoporosis and breast cancer, a respiratory drug, Ariflo and a new highly-potent an tibiotic.
The company also has under development idoxifene for osteoporosis and rosiglitazone, a Type 2 diabetes drug of the same class - but, according to analysts, without the same side effects - as the troglitazone drug Glaxo withdrew before Christmas.